Quironsalud Madrid
Biaya imunoterapi di Spanyol biasanya berkisar dari $12,000 hingga $25,000. Harga bervariasi tergantung pada jenis imunoterapi yang digunakan (seperti antibodi monoklonal, inhibitor checkpoint, atau terapi sel CAR-T), jumlah siklus pengobatan, klinik, dan keahlian dokter yang merawat. Di Amerika Serikat, harga rata-rata adalah $30,000 (menurut American Cancer Society). Ini berarti imunoterapi di Spanyol bisa sekitar 38% lebih murah dibandingkan di AS.
Klinik di Spanyol biasanya mencakup konsultasi awal, tes diagnostik, pemberian obat, pemantauan selama pengobatan, dan kunjungan lanjutan yang dijadwalkan dalam keseluruhan biaya. Di AS, harga yang terdaftar sering kali hanya mencakup obat, dengan biaya terpisah untuk kunjungan dokter, tes laboratorium, dan layanan infus. Selalu konfirmasi secara tepat apa yang termasuk di setiap klinik.
Mengapa memilih Spanyol untuk imunoterapi?
Akses solusi Imunoterapi canggih di klinik terpercaya .
| Turki | Austria | Espanha | |
| Imunoterapi | dari $2,200 | dari $30,000 | dari $12,000 |
| Terapi biologis | dari $5,500 | dari $20,000 | dari $15,000 |
| Terapi Bacillus Calmette-Guérin (BCG) | dari $1,200 | dari $2,400 | dari $3,200 |
| Imunoterapi untuk kanker prostat | dari $12,000 | dari $30,000 | dari $35,000 |
| Imunoterapi untuk kanker payudara | dari $9,500 | dari $35,000 | dari $45,000 |
Bookimed tidak menambah biaya tambahan dalam harga Imunoterapi. Tarif berasal dari daftar harga resmi klinik. Anda membayar langsung di klinik untuk Imunoterapi Anda saat tiba.
Bookimed berkomitmen pada keselamatan Anda. Kami hanya bekerja dengan institusi medis yang menjaga standar internasional tinggi dalam Imunoterapi dan memiliki izin yang dibutuhkan untuk melayani pasien internasional di seluruh dunia.
Bookimed menawarkan bantuan ahli gratis. Koordinator medis pribadi mendukung Anda sebelum, selama, dan setelah perawatan, menyelesaikan semua masalah Anda. Anda tidak pernah sendirian dalam perjalanan Imunoterapi Anda.
Dr. Graupera memimpin Departemen Hematologi Onkologi di Sant Joan De Déu – salah satu rumah sakit anak terbaik di Eropa. Penelitiannya berfokus pada pengobatan kanker pediatrik.
Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.
She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.
She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.
Pakar terkemuka dunia dalam Leukemia Limfositik Kronis (LLK) – Profesor Bosch memimpin lebih dari 80 uji klinis mengenai pengobatan baru.
Peneliti Utama dalam uji klinis yang berfokus pada imunoterapi untuk kanker ginekologi – Dr. Oaknin memimpin penelitian mutakhir di Hospital Quiron Barcelona.
Spain provides advanced immunotherapy options including checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies. Leading centers like Centro Médico Teknon and Clínica Universidad de Navarra utilize biomarker-driven precision oncology to treat lung, breast, and hematologic cancers with drugs like Keytruda and Opdivo.
Bookimed Expert Insight: Spain stands out globally for institutional clinical trials. At Quironsalud Madrid, patients may qualify for free access to next-generation immunotherapy through active trials. Always confirm if your specific cancer markers, like PD-L1 or MSI, have been tested. These results often dictate which high-cost drugs clinics will approve for your case.
Patient Consensus: Patients recommend confirming the exact drug protocol and biomarker requirements early. Many highlight the importance of reporting immune-related side effects, such as fatigue or rashes, immediately to the clinical team.
Spain features internationally accredited institutions specialized in cutting-edge oncological care. Top hospitals for cancer immunotherapy include Clinica Universidad de Navarra, Centro Medico Teknon, and MD Anderson Cancer Center Madrid. These centers offer advanced checkpoint inhibitors, personalized biomarker matching, and access to international clinical trials.
Bookimed Expert Insight: Spain's oncology landscape is unique because private centers like Clinica Universidad de Navarra often lead in JCI certifications. However, our data shows institutional clusters in Madrid and Barcelona provide the best access to multidisciplinary tumor boards. For complex immunotherapy, look for clinics like Quironsalud Madrid that host over 20+ active Phase II and III trials.
Patient Consensus: Patients prioritize clinics with in-house molecular labs for PD-L1 testing and tumor board reviews. Many suggest visiting these reference centers in Madrid or Barcelona specifically for treatment planning before starting regimens.
International patients can access immunotherapy clinical trials in Spain through private centers and research hubs, though eligibility is determined on a case-by-case basis. Spain leads European oncology research, with clinics like Quironsalud Madrid offering free treatment for eligible participants in active Phase I-III studies.
Bookimed Expert Insight: While major centers like Quironsalud Barcelona and Teknon Medical Center serve thousands of international patients, trial success often depends on specialized units. For instance, Dr. Francesc Bosch at Quironsalud Barcelona currently manages over 80 Phase I-III trials. Patients should target institutions where principal investigators have a high volume of registration-enabling trials, as these clinics often have the most robust infrastructure for international enrollment and safety reporting.
Patient Consensus: Success depends on having a complete medical dossier ready, including translated pathology reports and specific biomarker panels like PD-L1 or MSI. Many find that early-phase trials are logistically difficult due to frequent monitoring, making later-phase studies more practical for those traveling from abroad.